https://assets.capyfin.com/instruments/678fdc13234e27009c5d5cca.png avatar
Boston Scientific
🇺🇸 NYSE:BSX
View Company
OverviewEarningsDividends
•
Mar 31, 2022

Boston Scientific Q1 2022 Earnings Report

Boston Scientific's first quarter 2022 results were announced, demonstrating growth driven by strong execution, portfolio innovation, and improved procedure volume.

Key Takeaways

Boston Scientific reported net sales of $3.026 billion for the first quarter of 2022, representing a 10.0% increase on a reported basis and an adjusted EPS of $0.39. The company's growth was fueled by strong execution, an innovative portfolio, and improved procedure volume.

Net sales reached $3.026 billion, a 10.0% increase reported.

GAAP net income available to common stockholders was $0.07 per share.

Adjusted EPS was $0.39 per share.

Net sales growth was achieved across all reportable segments.

Total Revenue
$3.03B
Previous year: $2.75B
+10.0%
EPS
$0.39
Previous year: $0.37
+5.4%
MedSurg Organic Revenue Growth
8%
Previous year: 9.5%
-15.8%
Cardio Organic Revenue Growth
10.8%
Previous year: 7.4%
+45.9%
Gross Profit
$2.07B
Previous year: $1.86B
+11.5%
Cash and Equivalents
$325M
Previous year: $2.02B
-83.9%
Free Cash Flow
-$179M
Previous year: $209M
-185.6%
Total Assets
$32.3B
Previous year: $30.9B
+4.7%

Boston Scientific

Boston Scientific

Boston Scientific Revenue by Segment

Boston Scientific Revenue by Geographic Location

Forward Guidance

The company estimates net sales growth for the full year 2022 to be in the range of approximately 7 to 9 percent on a reported basis, and EPS on a GAAP basis in a range of $0.78 to $0.88 and estimates adjusted EPS of $1.74 to $1.79. For the second quarter of 2022, the company estimates net sales growth to be in a range of approximately 3 to 6 percent on a reported basis and EPS on a GAAP basis in a range of $0.19 to $0.23 and adjusted EPS of $0.41 to $0.43.

Positive Outlook

  • Full year 2022 net sales growth is estimated to be in a range of 7 to 9 percent on a reported basis.
  • Full year 2022 organic net sales growth is estimated to be in a range of approximately 6.5 to 8.5 percent.
  • Full year 2022 EPS on a GAAP basis is estimated in a range of $0.78 to $0.88.
  • Full year 2022 adjusted EPS is estimated in a range of $1.74 to $1.79.
  • Second quarter 2022 net sales growth is estimated to be in a range of approximately 3 to 6 percent on a reported basis.

Challenges Ahead

  • Second quarter 2022 organic net sales growth is estimated to be in a range of approximately 3 to 6 percent.
  • Second quarter 2022 EPS on a GAAP basis is estimated in a range of $0.19 to $0.23.
  • Second quarter 2022 adjusted EPS is estimated in a range of $0.41 to $0.43.
  • Full year organic net sales guidance excludes the impact of foreign currency fluctuations
  • Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Boston Scientific